[
  {
    "criterion": "Mentions specific PARP inhibitors or monoclonal antibodies for maintenance therapy",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Does not provide any specific regimen for reducing the risk of recurrence",
    "axis": "completeness",
    "point": -8
  },
  {
    "criterion": "Asks for more information about the patient's previous treatment responses or comorbidities",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Provides overly technical or professional medical information",
    "axis": "communication_quality",
    "point": -6
  },
  {
    "criterion": "Does not address the patient's concern about the potential toxicity of the proposed regimen",
    "axis": "instruction_following",
    "point": -4
  },
  {
    "criterion": "Mentions the importance of comparing the patient's profile to other maintenance therapy options",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Falsely claims that quimioterapia metron√≥mica in low doses has been proven effective in large studies",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Does not provide any information about the patient's quality of life",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Correctly states that there is limited evidence for maintenance therapy in ovarian cancer",
    "axis": "accuracy",
    "point": 7
  },
  {
    "criterion": "Asks the user to clarify the patient's response to previous treatments",
    "axis": "context_awareness",
    "point": 5
  }
]